Brooke Hoppe

Brooke Hoppe

Auto-generated profile, based on publicly available information

Brooke Hoppe

Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2023 in The American Journal of Pathology
Verified
Journal Article
Open access
SHStefan C. Halvorsen
Stefan C. Halvorsen
YBYair Benita
Yair Benita
MHMegan Hopton
Megan Hopton
BHBrooke Hoppe
Brooke Hoppe
HGHilmar O. Gunnlaugsson
Hilmar O. Gunnlaugsson
SSSlim Sassi
Slim Sassi
Chordoma is a rare malignant tumor demonstrating notochordal differentiation. It is dependent on brachyury (TBXT), a hallmark notochordal gene and transcription factor, and shares histologic features and the same anatomic location as the notochord. This study involved a molecular comparison of chordoma and notochord to identify dysregulated cellular pathways. The lack of a molecular reference from appropriate control tissue limits our understanding of chordoma and its relationship to notochord. Therefore, an unbiased comparison of chordoma, human notochord, and an atlas of normal and cancerous tissue was conducted using gene expression profiling to clarify the chordoma/notochord relationship and potentially identify novel drug targets. The study found striking consistency in gene expression profiles between chordoma and notochord, supporting the hypothesis that chordoma develops from notochordal remnants. A 12-gene diagnostic chordoma signature was identified and the TBXT/transforming growth factor beta (TGF-β)/SOX6/SOX9 pathway was hyperactivated in the tumor, suggesting that pathways associated with chondrogenesis were a central driver of chordoma development. Experimental validation in chordoma cells confirmed these findings and emphasized the dependence of chordoma proliferation and survival on TGF-β. The computational and experimental evidence provided the first molecular connection between notochord and chordoma and identified core members of a chordoma regulatory pathway involving TBXT. This pathway provides new therapeutic targets for this unique malignant neoplasm and highlights TGF-β as a prime druggable candidate.

28 June 2024 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JGJoseph P. Gallant
Joseph P. Gallant
DHDustin Hicks
Dustin Hicks
KSKe Shi
Ke Shi
NMNicholas H. Moeller
Nicholas H. Moeller
BHBrooke Hoppe
Brooke Hoppe
ALAaron M. LeBeau
Aaron M. LeBeau
Opioid use disorders (OUD) and overdoses are ever-evolving public health threats that continue to grow in incidence and prevalence in the United States and abroad. Current treatments consist of opioid receptor agonists and antagonists, which are safe and effective but still suffer from some limitations. Murine and humanized monoclonal antibodies (mAb) have emerged as an alternative and complementary strategy to reverse and prevent opioid-induced respiratory depression. To explore antibody applications beyond traditional heavy-light chain mAbs, we identified and biophysically characterized a novel single-domain antibody specific for fentanyl from a camelid variable-heavy-heavy (VHH) domain phage display library. Structural data suggested that VHH binding to fentanyl was facilitated by a unique domain-swapped dimerization mechanism, which accompanied a rearrangement of complementarity-determining region loops leading to the formation of a fentanyl-binding pocket. Structure-guided mutagenesis further identified an amino acid substitution that improved the affinity and relaxed the requirement for dimerization of the VHH in fentanyl binding. Our studies demonstrate VHH engagement of an opioid and inform on how to further engineer a VHH for enhanced stability and efficacy, laying the groundwork for exploring the in vivo applications of VHH-based biologics against OUD and overdose.

10 October 2025 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
CBCarly Baehr
Carly Baehr
EHEduardo Hatschbach
Eduardo Hatschbach
JVJennifer Vigliaturo
Jennifer Vigliaturo
DHDustin Hicks
Dustin Hicks
SPSujata Pandit
Sujata Pandit
MPMarco Pravetoni
Marco Pravetoni

1 December 2022 in ACS Omega
Verified
Journal Article
Open access
ALAlbert Y. Liu
Albert Y. Liu
XCXavier A. Calicdan
Xavier A. Calicdan
GGGene N. Glover
Gene N. Glover
XLXue Luo
Xue Luo
GBGage T. Barroso
Gage T. Barroso
LWLeah S. Witus
Leah S. Witus
Peptide catalysts for a wide diversity of reaction types contain a common motif-residues that bias the sequence toward beta-turn secondary structure. In this work, we explore what role that secondary structure plays in the catalysis of aldol reactions for primary amine tetrapeptide aldol catalysts. Using a lead tetrapeptide beta-turn catalytic sequence, we varied the i + 1 and i + 2 residues to amino acids that would affect the beta-turn propensity. We then studied the correlation between secondary structure, aldol rate enhancement, and stereoselectivity of the reaction between hydroxyacetone and 4-nitrobenzaldehyde. Using the i + 3 amide chemical shift as a measure of beta-turn character, we found a rough correlation between the peptide structure and reaction kinetics but minimal effect on stereoselectivity. These trends may help aid the design of future catalytic sequences.

10 May 2025 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
BHBrooke K. Hoppe
Brooke K. Hoppe
RJRobert W. Seaman Jr
Robert W. Seaman Jr
BHBryan Hannon
Bryan Hannon
EGElaine Gay
Elaine Gay
DHDustin Hicks
Dustin Hicks
MPMarco Pravetoni
Marco Pravetoni

13 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
FHFatima A Hamid
Fatima A Hamid
NLNguyet-Minh Nguyen Le
Nguyet-Minh Nguyen Le
DSDaihyun Song
Daihyun Song
HAHardik Amin
Hardik Amin
LHLinda Hicks
Linda Hicks
MPMarco Pravetoni
Marco Pravetoni
The U.S. opioid epidemic is an extraordinary public health crisis that started in 1990 and significantly accelerated in the last decade. Since 2020, over 100,000 fatal drug overdoses have been reported annually, and 75% of those involved fentanyl and its analogs (F/FA). Accelerating the translation of innovative, effective, and safe treatments is needed to augment existing measures to counteract such a crisis. Active immunization against F/FA and other opioids represents a promising therapeutic and prophylactic strategy for opioid use disorder (OUD) and opioid-induced overdose toxicity. Previously we demonstrated that the anti-fentanyl vaccine comprising a fentanyl-based hapten (F) conjugated to the diphtheria cross-reactive material (CRM), admixed with the novel lipidated toll-like receptor 7/8 (TLR7/8) agonist INI-4001 adsorbed on Alhydrogel ® (alum) induced high-affinity fentanyl-specific polyclonal antibodies that protected against fentanyl-induced pharmacological effects in mice, rats, and mini-pigs. Here, INI-4001 was formulated into liposomes with different surface charges, and their impact on F-CRM adsorption, INI-4001 adjuvanticity, and vaccine efficacy were explored. Additionally, as the role of innate immunity in mediating the efficacy of addiction vaccines is largely unknown, we tested these formulations on the activation of innate immunity in vitro . Cationic INI-4001 liposomes surpassed other liposomal and aluminum-based formulations of INI-4001 by enhancing the efficacy of fentanyl vaccines and protecting rats against bradycardia and respiratory depression by blocking the distribution of fentanyl to the brain. Fentanyl vaccines adjuvanted with either cationic INI-4001 liposomes or the aqueous INI-4001 adsorbed to alum induced significant surface expression of co-stimulatory molecules and maturation markers in a murine dendritic cell line (JAWS II), while the former was superior in enhancing the macrophages surface expression of CD40, CD86 and inducible nitric oxide synthase (iNOS), indicative of maturation and activation. These results warrant further investigation of liposome-based formulations of TLR7/8 agonists for improving the efficacy of vaccines targeting F/FA and other opioids of public health interest. Graphical